文献速递胸部肿瘤

EORTC LCG-1613 APPLE试验:奥希替尼对比吉非替尼后序贯奥希替尼治疗晚期EGFR突变非小细胞肺癌的总生存

Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2024-02-07

APPLE II期试验纳入156例初治晚期EGFR突变NSCLC患者,评估一线奥希替尼或吉非替尼后序贯奥希替尼策略。一线奥希替尼与序贯策略总生存相似(HR 1.01,90%CI 0.61-1.68),但序贯策略脑进展风险更高(HR 0.54,90%CI 0.34-0.86)。

要点

  • 一线奥希替尼较序贯策略降低脑进展风险(HR 0.54,90%CI 0.34-0.86)
  • 两策略总生存相似(HR 1.01,90%CI 0.61-1.68),18个月生存率84% vs 82.3%
  • 序贯组基线脑转移比例较高(29% vs 19%)

核心结论

  • APPLE试验提示序贯治疗策略与更频繁的脑进展相关,但在晚期EGFR突变NSCLC中生存相似。

研究设计与样本

  • II期APPLE试验(NCT02856893)纳入156例初治患者,评估一线奥希替尼或序贯策略(一线吉非替尼,进展时序贯奥希替尼)。

主要发现

  • 一线奥希替尼较序贯策略脑进展风险更低(HR 0.54,90%CI 0.34-0.86)。
  • 两策略总生存相似(HR 1.01,90%CI 0.61-1.68),18个月生存概率分别为84%和82.3%。
  • 按方案,序贯组73%的患者转换为奥希替尼。
  • 两组基线特征均衡,但序贯组基线脑转移比例更高(29% vs 19%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Osimertinib has been established as a standard of care for patients with common sensitizing EGFR-mutant advanced non-small-cell lung cancer (NSCLC) although the sequential approach (first-generation inhibitor gefitinib followed by osimertinib) has not been formally compared. The phase II APPLE trial (ClinicalTrials.gov identifier: NCT02856893) enrolled 156 treatment-naïve patients, and two treatment strategies were evaluated: osimertinib up front or the sequential treatment approach with gefitinib up front followed by osimertinib at the time of progression, either molecular progression (detection of plasma T790M resistance mutation) regardless of the radiologic status or just at the time of radiologic progression. Patients' characteristics were well balanced, except for the higher proportion of baseline brain metastases in the sequential approach (29% v 19%). Per protocol, 73% of patients switched to osimertinib in the sequential arm. Up-front treatment with osimertinib was associated with a lower risk of brain progression versus the sequential approach (hazard ratio [HR], 0.54 [90% CI, 0.34 to 0.86]), but a comparable overall survival was observed between both strategies (HR, 1.01 [90% CI, 0.61 to 1.68]), with the 18-month survival probability of 84% and 82.3%, respectively. The APPLE trial suggests that a sequential treatment approach is associated with more frequent progression in the brain but a similar survival in advanced EGFR-mutant NSCLC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Remon J, Besse B, Aix SP, et al. Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. J Clin Oncol. 2024. PMID: 38324744. doi:10.1200/JCO.23.01521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。